Stock · AJANTPHARM · Healthcare
AJANTPHARM share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for AJANTA PHARMA LIMITED, refreshed every end-of-day run. A systematic, data-only read on AJANTA PHARMA LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads AJANTPHARM as constructive with a Crack Score of 89/100 as of 25 Jul 2026.
BazaarBaaziSource & method
The scanner's readScanned · scanned 24 Jul 2026
Where AJANTPHARM stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
Scanned and scored this run, but the evidence is incomplete or conflicted. The engine fails closed to NO_TRADE.
Technical axis
100/100Fundamental axis
33/100Money flow
81/100Result pulse · Q4 FY26
0/100Technical evidence
price above 50DMA
price above 150DMA
price above 200DMA
50 > 150 > 200 DMA (clean stack)
uptrend frame (50 > 200 DMA)
50DMA rising
pulled back to a rising MA
orderly dip from highs
Red flags
above 200DMA (not a confirmed short-side trend)
strong accumulation tape
weak filed result (score 0.0)
Relative valuation
P/E (TTM)
40.7P/E vs sector
+0.8%Sector percentile
40PEG
n/aScanner levels from the deterministic engine run of 2026-07-24, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 25 Jul 2026
Support and resistance for AJANTPHARM are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the AJANTPHARM chart, refreshed every end-of-day run.
The Crack Score, and how it is built89 / 100 · High conviction
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for AJANTPHARM, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on AJANTPHARM reads right now.
The editorial price read on AJANTPHARM is bullish. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on AJANTPHARM can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving AJANTPHARM.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why AJANTPHARM moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
AJANTA PHARMA LIMITED's most recent quarter, parsed straight from the official BSE filing. Every figure links back to its primary source.
Result Pulse
0 / 100Revenue
Rs 1,422 crNet profit
Rs 267 crEPS (quarter)
Rs 21.35| Growth | YoY | QoQ |
|---|---|---|
| Revenue | n/a | n/a |
| Net profit | n/a | n/a |
| Net margin | n/a | |
Figures are the Q4 FY26 result for AJANTA PHARMA LIMITED, parsed straight from the official BSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter32 quarters on record
AJANTA PHARMA LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Jun 2018. These are quarterly facts, not TTM valuation inputs.
AJANTPHARM official result trail
32 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 1,422 cr | Rs 21.35 | n/a | n/a | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 1,375 cr | Rs 21.91 | n/a | 58/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 1,354 cr | Rs 20.83 | n/a | n/a | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 1,303 cr | Rs 20.44 | n/a | 58/100 | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 1,170 cr | Rs 18.00 | n/a | n/a | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 1,146 cr | Rs 18.60 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 1,187 cr | Rs 17.27 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 1,145 cr | Rs 19.54 | n/a | n/a | Filing |
| Q4 FY24ended 31 Mar 2024 / Consolidated, audited | Rs 1,054 cr | Rs 16.10 | n/a | n/a | Filing |
| Q3 FY24ended 31 Dec 2023 / Consolidated, audited | Rs 1,105 cr | Rs 16.68 | n/a | n/a | Filing |
| Q2 FY24ended 30 Sep 2023 / Consolidated, audited | Rs 1,028 cr | Rs 15.51 | n/a | n/a | Filing |
| Q1 FY24ended 30 Jun 2023 / Consolidated, audited | Rs 1,021 cr | Rs 16.53 | n/a | n/a | Filing |
| Q4 FY23ended 31 Mar 2023 / Consolidated, audited | Rs 882 cr | Rs 9.54 | n/a | n/a | Filing |
| Q3 FY23ended 31 Dec 2022 / Consolidated, audited | Rs 972 cr | Rs 10.50 | n/a | n/a | Filing |
| Q2 FY23ended 30 Sep 2022 / Consolidated, audited | Rs 938 cr | Rs 12.22 | n/a | n/a | Filing |
| Q1 FY23ended 30 Jun 2022 / Consolidated, audited | Rs 951 cr | Rs 13.63 | n/a | n/a | Filing |
| Q4 FY22ended 31 Mar 2022 / Consolidated, audited | Rs 870 cr | Rs 17.70 | n/a | n/a | Filing |
| Q3 FY22ended 31 Dec 2021 / Consolidated, audited | Rs 838 cr | Rs 22.16 | n/a | n/a | Filing |
| Q2 FY22ended 30 Sep 2021 / Consolidated, audited | Rs 885 cr | Rs 22.64 | n/a | n/a | Filing |
| Q1 FY22ended 30 Jun 2021 / Consolidated, audited | Rs 748 cr | Rs 20.08 | n/a | n/a | Filing |
| Q4 FY21ended 31 Mar 2021 / Consolidated, audited | Rs 757 cr | Rs 18.40 | n/a | n/a | Filing |
| Q3 FY21ended 31 Dec 2020 / Consolidated, audited | Rs 749 cr | Rs 20.41 | n/a | n/a | Filing |
| Q2 FY21ended 30 Sep 2020 / Consolidated, audited | Rs 716 cr | Rs 19.51 | n/a | n/a | Filing |
| Q1 FY21ended 30 Jun 2020 / Consolidated, audited | Rs 668 cr | Rs 16.93 | n/a | n/a | Filing |
| Q4 FY20ended 31 Mar 2020 / Consolidated, audited | Rs 682 cr | Rs 14.80 | n/a | n/a | Filing |
| Q3 FY20ended 31 Dec 2019 / Consolidated, audited | Rs 651 cr | Rs 12.33 | n/a | n/a | Filing |
| Q2 FY20ended 30 Sep 2019 / Consolidated, audited | Rs 643 cr | Rs 13.34 | n/a | n/a | Filing |
| Q1 FY20ended 30 Jun 2019 / Consolidated, audited | Rs 612 cr | Rs 13.14 | n/a | n/a | Filing |
| Q4 FY19ended 31 Mar 2019 / Consolidated, audited | Rs 515 cr | Rs 10.10 | n/a | n/a | Filing |
| Q3 FY19ended 31 Dec 2018 / Consolidated, audited | Rs 485 cr | Rs 7.60 | n/a | n/a | Filing |
| Q2 FY19ended 30 Sep 2018 / Consolidated, audited | Rs 544 cr | Rs 14.25 | n/a | n/a | Filing |
| Q1 FY19ended 30 Jun 2018 / Consolidated, audited | Rs 511 cr | Rs 12.02 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
AJANTA PHARMA LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
5,453 crNet profit (TTM)
1,056 crEBIT (TTM)
1,394 crProfit before tax (TTM)
1,378 crNet margin (TTM)
19.4%Finance costs (TTM)
16.1 crBalance sheet, as filed 2026-03-31
Total assets
6,155 crShareholder equity
4,527 crTotal borrowings
212 crCash and equivalents
103 crInventory
939 crTrade receivables
1,854 crThe cash engine, latest filed year
Operating cash flow
529 crCapex
365 crFree cash flow
164 crInvesting flow
429 crFinancing flow
168 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 5,453 cr | 1,056 cr | 4,527 cr | 212 cr | 529 cr |
| FY25 | 4,648 cr | 920 cr | 3,790 cr | 2.6 cr | 1,157 cr |
| FY24 | 4,209 cr | 816 cr | 3,567 cr | 1.5 cr | 785 cr |
| FY23 | 3,743 cr | 588 cr | 3,388 cr | 1.4 cr | 792 cr |
| FY22 | 3,341 cr | 713 cr | 3,264 cr | 1.9 cr | 562 cr |
| FY21 | 2,890 cr | 654 cr | 2,996 cr | 1.6 cr | n/a |
Every figure is parsed from AJANTA PHARMA LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record3 earnings calls
Every AJANTPHARM earnings call BazaarBaazi has indexed, latest 31 May 2026. Read management in its own words, straight from the filed transcript.
AJANTA PHARMA LIMITED earnings calls on record
3 calls since 31 Aug 2022
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed1 disclosure
Every recent official filing from AJANTA PHARMA LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
AJANTA PHARMA LIMITED's most recent official filing is a Earnings dated 31 Mar 2026.
Event Heat
61 / 100Event Heat is a dated net read of AJANTA PHARMA LIMITED's last 180 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the AJANTPHARM chart. Not a substitute for a registered research note.
| Ticker | AJANTPHARM |
|---|---|
| Full name | AJANTA PHARMA LIMITED |
| Sector | Healthcare |
| Index class | MID CAP |
| ISIN | INE031B01049 |
| Market-cap band | ~44,662 cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | AJANTPHARM |
Reference chartLevels in show
The daily frame the desk reads on AJANTPHARM.
FAQ11 reader questions · AEO-eligible
The line on AJANTPHARM, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the AJANTPHARM share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on AJANTPHARM. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for AJANTPHARM?
The BazaarBaazi Crack Score for AJANTPHARM is 89 out of 100 as of 25 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on AJANTPHARM?
Strike-level option inventory for AJANTPHARM is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is AJANTPHARM in and which peers does BazaarBaazi track?
AJANTPHARM sits in Healthcare (mid cap), indicative market cap ~44,662 cr (indicative), ISIN INE031B01049. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on AJANTA PHARMA LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the AJANTPHARM view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on AJANTPHARM is bullish, published in Systematic Read on 21 Jul 2026.
Is AJANTPHARM a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-24 run of the 500-name BazaarBaazi setup scanner, AJANTA PHARMA LIMITED sits in the Scanned tier with a setup score of 77/100 (technical 100, fundamental 33). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read AJANTA PHARMA LIMITED's earnings call transcripts?
BazaarBaazi indexes 3 AJANTPHARM earnings calls going back to 2022-08-31, latest 2026-05-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was AJANTA PHARMA LIMITED's Q4 FY26 net profit?
AJANTA PHARMA LIMITED reported a net profit of Rs 267 cr for Q4 FY26 (the quarter ended 31 March 2026). The figure is from the company's official NSE filing.
What was AJANTA PHARMA LIMITED's Q4 FY26 revenue?
AJANTA PHARMA LIMITED reported revenue of Rs 1,422 cr for Q4 FY26. The figure is from the company's official NSE filing.
How does BazaarBaazi rate AJANTA PHARMA LIMITED's Q4 FY26 result?
BazaarBaazi gives AJANTA PHARMA LIMITED's Q4 FY26 result a Result Pulse of 0 out of 100, with a verdict of Insufficient data. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Ajanta Pharma Ltd announced recently?
The most recent official filing on record for Ajanta Pharma Ltd is an earnings dated 31 Mar 2026. It is the company's own earnings disclosure to the exchange, and it links to that filing on the BazaarBaazi stock page rather than to any third-party summary.
Related stock views
The names BazaarBaazi reads alongside AJANTPHARM, each a living view refreshed every end-of-day run.